Pharmacyclics Inc. (PCYC)
-NasdaqCM 82.35 
2.36(2.79%) 4:00PM EDT|After Hours
:
83.22 0.87 (1.06%) 4:41PM EDT
| Prev Close: | 84.71 |
|---|
| Open: | 84.51 |
|---|
| Bid: | 70.31 x 200 |
|---|
| Ask: | 86.00 x 100 |
|---|
| 1y Target Est: | 98.91 |
|---|
| Beta: | 0.93 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 81.72 - 87.26 |
|---|
| 52wk Range: | 30.06 - 95.85 |
|---|
| Volume: | 579,490 |
|---|
| Avg Vol (3m): | 785,711 |
|---|
| Market Cap: | 5.99B |
|---|
| P/E (ttm): | 125.34 |
|---|
| EPS (ttm): | 0.66 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- FDA Designation for Synageva CandidateZacks(Wed 3:50PM EDT)
- 2013 FDA Drug Approval Calendarat TheStreet(Tue, May 21)
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue, May 21)
- Tackling Cancer: Leukemia's Biggest Current and Upcoming Playersat Motley Fool(Sun, May 19)
- Wall Street Transcript Interview with Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund: Investing in Health Care InnovationWall Street Transcript(Thu, May 16)
- PHARMACYCLICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- With 'Cell Death' Drugs, Bristol-Myers May Win No Matter Whatat Forbes(Wed, May 15)
- ASCO '13 Preview: Roche's Next-Gen Rituxan Steps Upat TheStreet(Wed, May 15)
- ASCO '13 Preview: Gilead's Big Cancer Debutat TheStreet(Wed, May 15)
- Three Value-Presenting Stocks With Upgrades on Mondayat Motley Fool(Wed, May 15)
- PHARMACYCLICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Submission of Matters to a Vote ofEDGAR Online(Tue, May 14)
- Pharmacyclics Rises On Unusually High Volume (PCYC)at TheStreet(Mon, May 13)
- 3 Biotech Stocks Spiking With Big Volumeat TheStreet(Mon, May 13)
- 6 Superstars For Your Biotech Portfolio: John McCamantat Seeking Alpha(Fri, May 10)
- Climbing the Wall of Worryat Motley Fool(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 37.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.90 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.04 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -612.06 |
|---|
Business Summary
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases.
View More